Literature DB >> 10023777

Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response.

D Novick1, S H Kim, G Fantuzzi, L L Reznikov, C A Dinarello, M Rubinstein.   

Abstract

An interleukin-18 binding protein (IL-18BP) was purified from urine by chromatography on IL-18 beads, sequenced, cloned, and expressed in COS7 cells. IL-18BP abolished IL-18 induction of interferon-gamma (IFNgamma), IL-8, and activation of NF-kappaB in vitro. Administration of IL-18BP to mice abrogated circulating IFNgamma following LPS. Thus, IL-18BP functions as an inhibitor of the early Th1 cytokine response. IL-18BP is constitutively expressed in the spleen, belongs to the immunoglobulin superfamily, and has limited homology to the IL-1 type II receptor. Its gene was localized on human chromosome 11q13, and no exon coding for a transmembrane domain was found in an 8.3 kb genomic sequence. Several Poxviruses encode putative proteins highly homologous to IL-18BP, suggesting that viral products may attenuate IL-18 and interfere with the cytotoxic T cell response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023777     DOI: 10.1016/s1074-7613(00)80013-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  212 in total

Review 1.  Interleukin-18, rheumatoid arthritis, and tissue destruction.

Authors:  J M Dayer
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

Authors:  A Bowie; E Kiss-Toth; J A Symons; G L Smith; S K Dower; L A O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease.

Authors:  Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

4.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 5.  Interleukin-18 as a potential target in inflammatory arthritis.

Authors:  J A Gracie
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

6.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist.

Authors:  Frank L van de Veerdonk; Angela K Stoeckman; Gouping Wu; Aaron N Boeckermann; Tania Azam; Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Ruyi Hao; Vassili Kalabokis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

7.  Blocking of interferon regulatory factor 1 reduces tumor necrosis factor α-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein a: role of the nuclear interferon regulatory factor 1-NF-κB-c-jun complex.

Authors:  Hubert Marotte; Pei-Suen Tsou; Bradley J Rabquer; Adam J Pinney; Tatiana Fedorova; Nalin Lalwani; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2011-11

8.  Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients.

Authors:  A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 9.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

10.  Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor.

Authors:  Eli C Lewis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.